Aquestive Therapeutics, Inc. (AQST)

Market Cap	319.35M
Revenue (ttm)	57.56M
Net Income (ttm)	-44.14M
Shares Out	98.87M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	968,097
Open	3.245
Previous Close	3.250
Day's Range	3.170 - 3.295
52-Week Range	2.240 - 5.800
Beta	2.76
Analysts	Strong Buy
Price Target	10.57 (+227.25%)
Earnings Date	Mar 5, 2025

About AQST

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder; and Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures. The company’s proprie...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 25, 2018
• Employees: 142
• Stock Exchange: NASDAQ
• Ticker Symbol: AQST
• Website: https://www.aquestive.com

Financial Performance

In 2024, Aquestive Therapeutics's revenue was $57.56 million, an increase of 13.80% compared to the previous year's $50.58 million. Losses were -$44.14 million, 460.8% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for AQST stock is "Strong Buy." The 12-month stock price forecast is $10.57, which is an increase of 227.25% from the latest price.

Price Target

$10.57

(227.25% upside)

Analyst Consensus: Strong Buy